Your source for recent licensing deal information
Knowledge about past deals is a crucial prerequisite for successful licensing negotiations. With a subscription to the Biotechgate Licensing Deals database you get online access to a comprehensive directory of therapeutic licensing deals with financial information from 1996 until today. As an alternative individual deal reports on specific big pharma companies, indications and development stages are offered.Targeted Deal Benchmark Reports
-
Search
Use the powerful text search engine or filter by categories.explore now
-
Unique dataset
Access 1'405 licensing deals, with financial information each.read more
-
Bookmarks
Bookmark your favorite deals and download your result lists to excel.learn more
View samples of deals below or do a search and see how many results you would get
Targeted Deal Benchmark Reports
So you want to licence your new compound but don't know where to start? Well, you may have
noticed from your personal experience that prior knowledge of the terms of past
deals are a crucial prerequisite for successful licensing negotiations.
Why don't you save time by taking advantage of our targeted licensing deal reports.
The Biotechgate benchmarking reports will provide you with the key information to get the most value out of your next licensing deal. Our targeted reports deliver vital information on deals for selected indications, product development phases and/or compound classes. Also, see what major players from big pharma companies are dealing in your markets. The reports are highly specific and contain invaluable information on the deal financials.
The targeted benchmarking reports provide deals with financial information specific to your area of interest in order to:
- Save time when benchmarking your next deal
- Cross reference with comparable deals
- Identify creative deal structures
- Follow deal making trends in your therapy area of interest
- Gain insight into how big pharma structure their licensing deals
Add value to your next deal by purchasing one of the reports below.
Oncology deals
| Specification | Order # | Min. no. of deals* | Price EUR** |
| Early stage oncology deals | OC-10 | 74 | 500.- |
| Phase I oncology deals | OC-20 | 47 | 500.- |
| Phase II oncology deals | OC-30 | 31 | 500.- |
| Phase III oncology deals | OC-50 | 40 | 500.- |
| Oncology - antibody deals | OC-60 | 51 | 500.- |
| Leukemia, lymphoma & multiple myeloma deals | OC-70 | 45 | 500.- |
| Prostate cancer | OC-80 | 29 | 500.- |
Click the button to order a report by downloading the order form and submitting the signed
form to us (by fax or e-mail, see address specified at the bottom of the document). You will then receive an invoice and once this is paid you will receive the
ordered report.
Big pharma licensees deals
| Licensee | Order # | Min. no. of deals* | Price EUR** |
| Astellas Pharma | BP-10 | 22 | 350.- |
| Boehringer Ingelheim | BP-20 | 24 | 350.- |
| BristolMyers Squibb | BP-30 | 43 | 500.- |
| GlaxoSmithKline | BP-40 | 89 | 500.- |
| Johnson & Johnson | BP-50 | 39 | 500.- |
| Merck & Co | BP-60 | 81 | 500.- |
| Novartis | BP-70 | 71 | 500.- |
| Pfizer | BP-80 | 98 | 500.- |
| Roche | BP-90 | 69 | 500.- |
| Sanofi | BP-100 | 63 | 500.- |
| Takeda Pharmaceutical Co | BP-110 | 40 | 500.- |
Early stage license deals
| Disease area | Order # | Min. no. of deals* | Price EUR** |
| Nervous system | ES-10 | 29 | 350.- |
| Infections | ES-20 | 43 | 500.- |
Deals by indication outside oncology field
| Indication | Order # | Min. no. of deals* | Price EUR** |
| Alzheimer & Parkinson | IN-10 | 50 | 500.- |
| Drug delivery | IN-20 | 58 | 500.- |
| Eye disorders | IN-30 | 40 | 500.- |
| Hepatitis B & C | IN-50 | 41 | 500.- |
| Pain | IN-60 | 62 | 500.- |
| Rheumatoid Arthritis | IN-70 | 35 | 500.- |
Click the button to order a report by downloading the order form and submitting the signed
form to us (by fax or e-mail, see address specified at the bottom of the document). You will then receive an invoice and once this is paid you will receive the
ordered report.
*minimum number of indicated deals. As we are constantly up-dating, you will get all the available deals in this category (count based on March 2012)
**excl. VAT/MWSt of 8.0% (applied to Swiss customers only)
